Feed Top Reports Pricing

⌘K

16:30:41·38d

SECFiling

SEC Form 10-K filed by Oragenics Inc.

OGEN· Oragenics Inc.

Health Care

Full content unavailable. See the original source below.

Original source

Companies

OGEN
Oragenics Inc.
Health Care

Related

PR4d
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
SEC11d
Oragenics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
PR11d
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
SEC23d
Oragenics Inc. filed SEC Form 8-K: Shareholder Director Nominations, Financial Statements and Exhibits
PR29d
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
SEC32d
SEC Form EFFECT filed by Oragenics Inc.
SEC35d
Amendment: SEC Form S-3/A filed by Oragenics Inc.
PR38d
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022